Tafenoquine
From Wikipedia, the free encyclopedia
Tafenoquine
|
|
Systematic (IUPAC) name | |
N-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl) phenoxy]quinolin-8-yl]pentane-1,4-diamine |
|
Identifiers | |
CAS number | |
ATC code | ? |
PubChem | |
Chemical data | |
Formula | C24H28F3N3O3 |
Mol. mass | 463.493 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Tafenoquine (also called WR-238605 or SB-252263) is an 8-aminoquinoline drug manufactured by GlaxoSmithKline that is currently being investigated as a potential treatment for malaria, as well as for malaria prevention.[1][2]
The main advantage of tafenoquine is that it has a long half-life and therefore does not need to be taken as frequently as primaquine. Like primaquine, tafenoquine causes haemolysis in people with G-6-PD deficiency.[1]
The dose of tafenoquine has not been firmly established, but for the treatment of Plasmodium vivax malaria, a dose of 800 mg over three days has been used.[3]
[edit] References
- ^ a b Shanks GD, Oloo AJ, Aleman GM, et al. (2001). "A New Primaquine Analogue, Tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria." ([dead link] – Scholar search). Clin Infect Dis 33: 1968–74. doi: .
- ^ Lell B, Faucher JF, Missinou MA, et al. (2000). "Malaria chemoprophylaxis with tafenoquine: a randomised study.". Lancet 355 (9220): 2041–5. doi: . PMID 10885356.
- ^ Nasvelda P, Kitchener S. (2005). "Treatment of acute vivax malaria with tafenoquine.". Trans R Soc Trop Med Hyg 99 (1): 2–5. doi: .